We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$440M
1-Year Est. Return
109.12%
This Fund
S&P 500
This Quarter
Est. Return
+11.1%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$440M
AUM Growth
+$9.07M
(+2.1%)
Cap. Flow
-$6.96M
Cap. Flow
% of AUM
-1.58%
Top 10 Holdings %
Top 10 Hldgs %
52.42%
Holding
87
New
10
Increased
20
Reduced
29
Closed
4
Top Buys
| 1 |
CMPS
Compass Pathways
CMPS
|
+$10.8M |
| 2 |
Nektar Therapeutics
NKTR
|
+$5.13M |
| 3 |
Larimar Therapeutics
LRMR
|
+$4.36M |
| 4 |
BCAX
Bicara Therapeutics
BCAX
|
+$2.76M |
| 5 |
Fulcrum Therapeutics
FULC
|
+$1.9M |
Top Sells
| 1 |
Cytokinetics
CYTK
|
+$9.76M |
| 2 |
Axogen
AXGN
|
+$7.38M |
| 3 |
ATXS
Astria Therapeutics
ATXS
|
+$3.99M |
| 4 |
Revolution Medicines
RVMD
|
+$2.41M |
| 5 |
State Street SPDR S&P Biotech ETF
XBI
|
+$2.25M |
Sector Composition
| 1 | Healthcare | 87.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Revolution Medicines
RVMD
$39.1B
| $56.5M | 12.85% |
580,678
-23,836
| -4% | -$2.41M |
|
|
2
State Street SPDR S&P Biotech ETF
XBI
$10.5B
| $40.7M | 9.25% |
318,505
-18,000
| -5% | -$2.25M |
|
3
Stereotaxis
STXS
$160M
| $25.2M | 5.73% |
13,680,554
| – | – |
|
|
DAWN
4
DELISTED
Day One Biopharmaceuticals
DAWN
| $21M | 4.77% |
978,463
-20,700
| -2% | -$292K |
|
5
AtriCure
ATRC
$1.78B
| $17M | 3.88% |
597,431
| – | – |
|
6
IDEAYA Biosciences
IDYA
$3.53B
| $15.9M | 3.61% |
476,740
-30,000
| -6% | -$1.01M |
|
7
Xenon Pharmaceuticals
XENE
$6.49B
| $14.6M | 3.32% |
250,772
-37,167
| -13% | -$1.71M |
|
|
8
Cytokinetics
CYTK
$11.2B
| $14.3M | 3.26% |
217,497
-153,500
| -41% | -$9.76M |
|
|
CMPS
9
Compass Pathways
CMPS
$1.73B
| $13.4M | 3.04% |
2,418,882
+1,607,836
| +198% | +$10.8M |
|
|
10
Nektar Therapeutics
NKTR
$2.26B
| $11.9M | 2.7% |
165,178
+90,180
| +120% | +$5.13M |
|
11
iShares Biotechnology ETF
IBB
$9.2B
| $10.5M | 2.39% |
62,095
-6,000
| -9% | -$1.03M |
|
12
Arcus Biosciences
RCUS
$3.51B
| $9.59M | 2.18% |
443,829
+12,500
| +3% | +$270K |
|
13
Neurocrine Biosciences
NBIX
$17.3B
| $9.3M | 2.12% |
70,615
| – | – |
|
|
14
Larimar Therapeutics
LRMR
$374M
| $9.13M | 2.08% |
2,029,164
+1,090,000
| +116% | +$4.36M |
|
|
BCAX
15
Bicara Therapeutics
BCAX
$1.83B
| $8.39M | 1.91% |
421,733
+160,150
| +61% | +$2.76M |
|
|
16
Axogen
AXGN
$2.05B
| $8.28M | 1.88% |
249,960
-226,866
| -48% | -$7.38M |
|
17
Biohaven
BHVN
$2.23B
| $7.15M | 1.63% |
845,735
-109,500
| -11% | -$1.2M |
|
18
Tandem Diabetes Care
TNDM
$1.08B
| $6.81M | 1.55% |
355,208
| – | – |
|
19
Denali Therapeutics
DNLI
$3.62B
| $6.12M | 1.39% |
318,500
| – | – |
|
20
Century Therapeutics
IPSC
$382M
| $5.5M | 1.25% |
2,434,353
-359,233
| -13% | -$755K |
|
21
DexCom
DXCM
$28.8B
| $5.42M | 1.23% |
86,279
-2,000
| -2% | -$139K |
|
|
KALV
22
DELISTED
KalVista Pharmaceuticals
KALV
| $5.38M | 1.22% |
267,402
-89,400
| -25% | -$1.44M |
|
23
Ascendis Pharma A/S
ASND
$17.4B
| $5.3M | 1.21% |
23,177
-5,000
| -18% | -$1.12M |
|
|
MBX
24
MBX Biosciences
MBX
$2.82B
| $5.24M | 1.19% |
175,465
+10,200
| +6% | +$347K |
|
25
Inogen
INGN
$173M
| $5.22M | 1.19% |
845,179
+18,108
| +2% | +$112K |
|
Similar funds
FGWP
STCG
SCP
CAAM
AWM
HCM
CPW
DWML